Cinven's M&A Ambitions Over Stada Under Scrutiny, Advent and Others Circle
Executive Summary
By stalking Stada, Cinven seems to be planning to use the German generics group as a base that can support later carve-outs of mature and undervalued products from larger pharma companies - but it faces a rival bidder in Advent, and more suitors could yet appear.
You may also be interested in...
Fearing Second Offer Failure, Stada Management Appeals To Shareholders
Stada's management is scared an offer from two private-equity suitors will fail a second time due to shareholder inactivity or reluctance to accept the deal before its Aug 16 deadline.
Fearing Second Offer Failure, Stada Management Appeals To Shareholders
Stada's management is scared an offer from two private-equity suitors will fail a second time due to shareholder inactivity or reluctance to accept the deal before its Aug 16 deadline.
Stada Bows To Activist AOC, Opens Bidding Process To Three Suitors
Stada's supervisory board says it will play cards the way Active Ownership Capital wants for the time being, and has now opened the M&A game centered on the German group to a "structured bidding process".